For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine ...
Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive metastatic breast cancer patients. The PATINA trial showed a median ...
– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and ...
Belamaf plus bortezomib and dexamethasone lengthened the time patients with relapsed or refractory myeloma lived before their disease got worse. For patients with relapsed or refractory myeloma, ...
A powerful, three-drug therapy for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
Molecular testing practice patterns for lung cancer based on gender: Insights into disparities and opportunities for precision medicine. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in median progression-free survival (PFS) by 2.9 months compared to fulvestrant in patients with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results